Ryvu Therapeutics Debt 2024

Ryvu Therapeutics Aktienanalyse

What does Ryvu Therapeutics do?

Ryvu Therapeutics SA is a Polish biotechnology company specializing in the research and development of innovative therapies for various types of cancers. The company was founded in 2015 and is headquartered in Krakow. Ryvu Therapeutics SA has gained a good reputation since its establishment and has attracted numerous renowned investors and partners. The company's business model focuses on the research and development of drugs based on new molecular therapies that can inhibit the activity of specific proteins in cancer patients. The company's strategy is to develop a wide range of innovative therapies with different mechanisms of action to maximize the potential of helping cancer patients. Ryvu Therapeutics SA operates in three main areas: research and development, preclinical development, and clinical development. The company has a highly experienced team of scientists and researchers dedicated to developing new anti-cancer drugs. The research focus is on identifying new therapeutic targets and molecules or compounds that can inhibit the activity of these targets. After identifying promising molecules in the research phase, the company conducts extensive preclinical studies to assess the safety and efficacy of the drug candidates. Different models are used to test the effects of the new therapies in vitro and in vivo. Upon successful completion of the preclinical phase, the company moves on to clinical development, where the effectiveness and safety of the drugs are evaluated in clinical trials in humans. Phase I clinical trials are conducted to determine the tolerability and dosage of the drug candidates. Phase II and III trials investigate the efficacy and safety of the drug in a larger number of patients. Ryvu Therapeutics SA has several molecules and compounds in its portfolio that are currently in different stages of development. Some examples include SEL120, a potential new drug that inhibits the activity of the CDK8 protein, which plays a crucial role in the development of cancer. SEL120 is currently in Phase I clinical trials. SEL201 is another drug candidate that targets CDK8 and is still in the preclinical research phase. SEL110 is a small molecule that targets the BCL-XL protein and has the potential to be effective against multiple types of cancer. It is currently in the early phase of clinical development. In conclusion, Ryvu Therapeutics SA is an innovative biotech company specializing in the development of new cancer therapies. The company already has several promising drug candidates in its portfolio, targeting different therapeutic targets and currently in various stages of development. Ryvu Therapeutics SA shows great potential to play a significant role in the treatment of cancer. Ryvu Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Ryvu Therapeutics's Debt Structure

Ryvu Therapeutics's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Ryvu Therapeutics's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Ryvu Therapeutics’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Ryvu Therapeutics’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Ryvu Therapeutics stock

What is the debt of Ryvu Therapeutics this year?

Ryvu Therapeutics has a debt level of 0.2 PLN this year.

What was the debt of Ryvu Therapeutics compared to the previous year?

The debt of Ryvu Therapeutics has increased by -100.08% compared to the previous year dropped.

What are the consequences of high debt for investors in Ryvu Therapeutics?

High debt can pose a risk for investors of Ryvu Therapeutics, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Ryvu Therapeutics?

Low debt means that Ryvu Therapeutics has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Ryvu Therapeutics affect the company?

An increase in debt of Ryvu Therapeutics can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Ryvu Therapeutics affect the company?

A reduction in debt of Ryvu Therapeutics can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Ryvu Therapeutics?

Some factors that can influence the debt of Ryvu Therapeutics include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Ryvu Therapeutics so important for investors?

The debts of Ryvu Therapeutics are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Ryvu Therapeutics take to change the debt?

To change the debt, Ryvu Therapeutics can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Ryvu Therapeutics pay?

Over the past 12 months, Ryvu Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Ryvu Therapeutics is expected to pay a dividend of 0 PLN.

What is the dividend yield of Ryvu Therapeutics?

The current dividend yield of Ryvu Therapeutics is .

When does Ryvu Therapeutics pay dividends?

Ryvu Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Ryvu Therapeutics?

Ryvu Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Ryvu Therapeutics?

For the upcoming 12 months, dividends amounting to 0 PLN are expected. This corresponds to a dividend yield of 0 %.

In which sector is Ryvu Therapeutics located?

Ryvu Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Ryvu Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Ryvu Therapeutics from 10/28/2024 amounting to 0 PLN, you needed to have the stock in your portfolio before the ex-date on 10/28/2024.

When did Ryvu Therapeutics pay the last dividend?

The last dividend was paid out on 10/28/2024.

What was the dividend of Ryvu Therapeutics in the year 2023?

In the year 2023, Ryvu Therapeutics distributed 0 PLN as dividends.

In which currency does Ryvu Therapeutics pay out the dividend?

The dividends of Ryvu Therapeutics are distributed in PLN.